Artrya Limited received advice that it has received regulatory approval for its Salix Coronary Anatomy (SCA) product in Europe. Artrya's European Notified Body (BSI) has notified the company that the assessment for European CE Marking has been completed and they will recommend certification of the Salix V2.0 Software for marketing into Europe. The BSI assessment scope includes European EC certification in accordance with the European Medical Device Regulations 2017/745.

Once the EC certificate has been issued by BSI, Artrya is able to market the Salix software in 28 European Economic Area member countries. The Conformite Europeenne Marking certifies that a product has met EU health, safety, and environmental requirements, which ensure consumer safety. On the basis of the Australian regulatory approval (ARTG 347719), the Salix Coronary Anatomy product received NZ Medsafe registration in July 2022.

This will allow the company to commercialise the product in the New Zealand market.